Boehringer Ingelheim has become the latest company to enter the growing market of tumour agnostic medicines with the first KRAS inhibitor. …
Boehringer Ingelheim looking to bring tumour-agnostic trials to Australia
October 31, 2019 Latest News
Latest Video
New Stories
-
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News -
MRFF program for issues identified by PBAC
December 12, 2019 - - Latest News -
MA board reappoints Dr Anna Lavelle
December 12, 2019 - - Latest News -
MSD announces US$2.7bn acquisition of ArQule
December 11, 2019 - - Latest News -
Sanofi narrows focus and scraps R&D in heritage areas
December 11, 2019 - - Latest News